U-69593

Name: U-69593
Brand: MedChemExpress
SKU: HY-12363
Rating: 4.5 (1 reviews)

Cat. No.: HY-12363 Purity: 99.73%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

U-69593 is a potent and selective κ1-opioid receptor agonist. U-69593 attenuates addictive agent-induced behavioral sensitization in the rat. U-69593 reduces anxiety and enhances spontaneous alternation memory in mice. U-69593 reduces calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum.

For research use only. We do not sell to patients.

U-69593 Chemical Structure

CAS No. : 96744-75-1

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	Get quote
50 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Opioid Receptor Isoform Specific Products:

View All Isoforms

μ Opioid Receptor/MOR κ Opioid Receptor/KOR δ Opioid Receptor/DOR NOP Receptor/ORL1

Biological Activity
Purity & Documentation
References
Customer Review

Description

U-69593 is a potent and selective κ1-opioid receptor agonist^[1]. U-69593 attenuates addictive agent-induced behavioral sensitization in the rat^[2]. U-69593 reduces anxiety and enhances spontaneous alternation memory in mice^[3]. U-69593 reduces calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum^[4].

IC₅₀ & Target

κ Opioid Receptor/KOR

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	0.63 nM Compound: U-69593	Binding affinity against rat kappa-opioid receptor expressed in CHO cells was determined by competitive inhibition of 2 nM [3H]-U 69593 Binding affinity against rat kappa-opioid receptor expressed in CHO cells was determined by competitive inhibition of 2 nM [3H]-U 69593	[PMID: 9873480]
CHO	EC₅₀	0.8 nM Compound: U69,593	Agonist activity at human KOR expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by luminescence assay Agonist activity at human KOR expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by luminescence assay	[PMID: 25426797]
CHO	EC₅₀	12.5 nM Compound: U-69593	Agonist activity at human recombinant kappa opioid receptor expressed in CHO cells assessed as calcium mobilization after 1 hrs by fluorescence analysis Agonist activity at human recombinant kappa opioid receptor expressed in CHO cells assessed as calcium mobilization after 1 hrs by fluorescence analysis	[PMID: 22464684]
CHO	EC₅₀	207 nM Compound: U-69593	Agonist activity at human kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding Agonist activity at human kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding	[PMID: 16441078]
CHO	EC₅₀	207 nM Compound: U-69593	Antagonist activity at human kappa opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay Antagonist activity at human kappa opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay	[PMID: 17580847]
CHO	EC₅₀	26.1 nM Compound: U69,593	Agonist activity at human kappa opioid receptor expressed in CHO cell membranes incubated for 60 mins by [35S]GTPgammaS binding assay Agonist activity at human kappa opioid receptor expressed in CHO cell membranes incubated for 60 mins by [35S]GTPgammaS binding assay	[PMID: 23134120]
CHO	EC₅₀	28.1 nM Compound: U-69,593	Agonist activity at human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by [35S]-GTPgammaS binding assay Agonist activity at human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by [35S]-GTPgammaS binding assay	[PMID: 23200250]
CHO	EC₅₀	28.1 nM Compound: U-69593	Agonist activity at human KOR expressed in CHO cell membranes by [35S]GTPgammaS binding assay Agonist activity at human KOR expressed in CHO cell membranes by [35S]GTPgammaS binding assay	[PMID: 26346669]
CHO	EC₅₀	28.1 nM Compound: U-69,593	Agonist activity at human kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 25283554]
CHO	EC₅₀	6.6 nM Compound: U-69593	Agonist activity at human kappa opioid receptor-Galpha-16 fusion protein expressed in CHO cells by calcium flux assay Agonist activity at human kappa opioid receptor-Galpha-16 fusion protein expressed in CHO cells by calcium flux assay	[PMID: 16441078]
CHO	EC₅₀	60.14 nM Compound: U69593	Agonist activity at human kappa opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis Agonist activity at human kappa opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis	[PMID: 24657054]
CHO	EC₅₀	7.7 nM Compound: U69593	Agonist activity at rat kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at rat kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 25221662]
CHO	EC₅₀	8.03 nM Compound: U-69,593	Agonist activity at human KOR expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human KOR expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 25248680]
HEK293	EC₅₀	12 nM Compound: U-69593	Agonist activity at human kappa opioid receptor expressed in HEK-293 cells assessed as stimulation of [35S]-GTPgammaS binding after 30 mins by liquid scintillation counting analysis Agonist activity at human kappa opioid receptor expressed in HEK-293 cells assessed as stimulation of [35S]-GTPgammaS binding after 30 mins by liquid scintillation counting analysis	[PMID: 25062506]
HEK293	EC₅₀	12 nM Compound: U-69593	Agonist activity at human kappa opioid receptor expressed in HEK-293 cells after 45 mins by [35S]GTP-gamma-S binding assay in presence of 10 uM of GDP Agonist activity at human kappa opioid receptor expressed in HEK-293 cells after 45 mins by [35S]GTP-gamma-S binding assay in presence of 10 uM of GDP	10.1039/C5MD00414D
HEK293	ED₅₀	24 nM Compound: U-69593	Effective dose for agonistic activity towards human kappa opioid receptor from membranes of HEK293 cells was determined by radiolabeled [35S]GTP-gamma-S, assay Effective dose for agonistic activity towards human kappa opioid receptor from membranes of HEK293 cells was determined by radiolabeled [35S]GTP-gamma-S, assay	[PMID: 12643930]
HEK293	EC₅₀	5.3 nM Compound: U-69,593	Agonist activity at recombinant human kappa-type opioid receptor expressed in HEK293 cells after 30 mins by [35S]GTPgammaS binding assay Agonist activity at recombinant human kappa-type opioid receptor expressed in HEK293 cells after 30 mins by [35S]GTPgammaS binding assay	[PMID: 28218838]
HEK293	EC₅₀	534 nM Compound: U69593	Agonist activity at GFP-fused kappa opioid receptor (unknown origin) expressed in HEK293 cells assessed as recruitment of beta-arrestin-2 after 10 mins by BRET assay Agonist activity at GFP-fused kappa opioid receptor (unknown origin) expressed in HEK293 cells assessed as recruitment of beta-arrestin-2 after 10 mins by BRET assay	[PMID: 24613457]
HEK293	EC₅₀	80 nM Compound: U-69593	Agonist activity at human recombinant kappa opioid receptor expressed in HEK293 cells assessed as stimulation of [35S]GTPgammaS binding after 45 mins by microplate luminescence assay Agonist activity at human recombinant kappa opioid receptor expressed in HEK293 cells assessed as stimulation of [35S]GTPgammaS binding after 45 mins by microplate luminescence assay	[PMID: 20441176]
HEK293	EC₅₀	80 nM Compound: U-69593	Agonist activity at recombinant kappa-opioid receptor in human HEK293 cells by [35S]-GTP-gammaS binding assay Agonist activity at recombinant kappa-opioid receptor in human HEK293 cells by [35S]-GTP-gammaS binding assay	[PMID: 24856182]
U2OS	EC₅₀	131 nM Compound: U69,593	Agonist activity at human kappa opioid receptor expressed in human U2OS cells co-transfected with EFC and beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 90 mins by luminescence assay Agonist activity at human kappa opioid receptor expressed in human U2OS cells co-transfected with EFC and beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 90 mins by luminescence assay	[PMID: 29939744]
U2OS	EC₅₀	205 nM Compound: U69,593	Agonist activity at human kappa opioid receptor expressed in human U2OS cells co-transfected with GFP and beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 20 mins by Hoechst staining-based assay Agonist activity at human kappa opioid receptor expressed in human U2OS cells co-transfected with GFP and beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 20 mins by Hoechst staining-based assay	[PMID: 29939744]
U2OS	EC₅₀	5.4 nM Compound: U69,593	Agonist activity at human kappa opioid receptor expressed in human U2OS cells assessed as increase in ERK1/2 phosphorylation after 10 mins by Western blot analysis Agonist activity at human kappa opioid receptor expressed in human U2OS cells assessed as increase in ERK1/2 phosphorylation after 10 mins by Western blot analysis	[PMID: 29939744]

In Vivo

U-69593 (0.16 mg/kg; s.c.) attenuates addictive agent-induced behavioral sensitization in the rat^[2].
U-69593 (1, 10, 25 nmol/μL; Microinjection) reduces anxiety and enhances spontaneous alternation memory in mice^[3].
U-69593 (0.32 mg/kg; s.c.) decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rat^[2]
Dosage:	0.16 mg/kg
Administration:	S.c. (an acute injection of cocaine (20 mg/kg i.p.))
Result:	Attenuated the acute and chronic effects of cocaine on locomotor activity and stereotypy.

Animal Model:	CD-1 mice^[3]
Dosage:	1, 10, 25 nmol/µL
Administration:	Microinjection (in the infralimbic cortex (IL)), once every week, 2 weeks
Result:	Dose-dependently prolonged transfer-latency (T-L) and produced a dose-dependent anxiolytic behavioural profile, and after 24 h, the mouse were observed small but detectable carry-over effects. In week 2, U-69593 dose-dependently prolonged T/L and produced an anxiolytic behavioural profile in the first EPM (elevated plus-maze) trial, but observed a robust anxiolytic behavioural profile.

Animal Model:	280-350 g, male Wistar rats^[4]
Dosage:	0.32 mg/kg
Administration:	S.c. (followed 15 min later by an injection of amphetamine (2.5 mg/kg i.p.))
Result:	Significantly reduced the amphetamine-stimulated increase in dialysate dopamine levels and blocked the ability of amphetamine to evoke an increase in dialysate glutamate levels.

Molecular Weight

356.50

Formula

C₂₂H₃₂N₂O₂

CAS No.

96744-75-1

Appearance

Solid

Color

White to off-white

SMILES

CN([C@@H]1[C@](N2CCCC2)([H])C[C@]3(CCCO3)CC1)C(CC4=CC=CC=C4)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMF : 10 mg/mL (28.05 mM; Need ultrasonic and warming)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8050 mL	14.0252 mL	28.0505 mL
5 mM	0.5610 mL	2.8050 mL	5.6101 mL
10 mM	0.2805 mL	1.4025 mL	2.8050 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.73%

Select Batch:

Data Sheet (276 KB) SDS (251 KB)

COA (250 KB) LCMS (96 KB)

Handling Instructions (2659 KB)

References

[1]. Lahti RA, et al. [3H]U-69593 a highly selective ligand for the opioid kappa receptor. Eur J Pharmacol. 1985 Feb 26;109(2):281-4. [Content Brief]

[2]. [2]Heidbreder CA, et al. The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat. Brain Res. 1993 Jul 9;616(1-2):335-8. [Content Brief]

[3]. [3]Wall PM, et al. U-69,593 microinjection in the infralimbic cortex reduces anxiety and enhances spontaneous alternation memory in mice. Brain Res. 2000 Feb 21;856(1-2):259-80. [Content Brief]

[4]. [4]Gray AM, et al. The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum. J Neurochem. 1999 Sep;73(3):1066-74. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMF	1 mM	2.8050 mL	14.0252 mL	28.0505 mL	70.1262 mL
	5 mM	0.5610 mL	2.8050 mL	5.6101 mL	14.0252 mL
	10 mM	0.2805 mL	1.4025 mL	2.8050 mL	7.0126 mL
	15 mM	0.1870 mL	0.9350 mL	1.8700 mL	4.6751 mL
	20 mM	0.1403 mL	0.7013 mL	1.4025 mL	3.5063 mL
	25 mM	0.1122 mL	0.5610 mL	1.1220 mL	2.8050 mL

U-69593 Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

U-6959396744-75-1U69593U 69593Opioid ReceptorSelectiveinfralimbic cortexanxietyspontaneous alternation memorydopamineglutamateInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

U-69593

Customer Review

U-69593 Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Opioid Receptor Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

U-69593 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report